CN107519236A - A kind of topical agent for treating onychomycosis - Google Patents
A kind of topical agent for treating onychomycosis Download PDFInfo
- Publication number
- CN107519236A CN107519236A CN201710817905.1A CN201710817905A CN107519236A CN 107519236 A CN107519236 A CN 107519236A CN 201710817905 A CN201710817905 A CN 201710817905A CN 107519236 A CN107519236 A CN 107519236A
- Authority
- CN
- China
- Prior art keywords
- parts
- oil
- onychomycosis
- add
- gels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of topical agent for treating onychomycosis, it is made up of A emulsifiable pastes, B gels, C liniment three parts, is made up of Extracts from Flowers of Impatiens balsamina L, basil oil, cinnamon oil, litsea citrate oil, eucalyptus oil, peppermint oil, Berberine hydrochloride, calcium mercaptoacetate, lactic acid, chlorhexidine acetate iodine etc..The medicament of the present invention outer therapeutic scheme for controlling onychomycosis different from the past, first with the quick painless first of preventing or cure a disease of A emulsifiable pastes, the deck barrier of nail matrix dispenser is dispelled, medicament is gone directly focus, revolutionize and generally go through the drawbacks of deck dispenser of disease first can not arrive at focus.B gels are used on the premise of nail matrix administration barrier is eliminated, it is rapid thoroughly to remove the pathogenic bacteria for killing lesions position, C liniment strong disinfectings, nail matrix and perionychium skin cleaning ambient are kept, reaches the effect not recurred.Multilayer stereo, anti-three doses are combined, Trinity therapy uniqueness, comprehensively solve onychomycosis quality problem with controlling, marking with this with controlling, and curative effect is reliable.
Description
Technical field
The present invention relates to the topical agent that one kind treats onychomycosis (onychomycosis).
Background technology
Onychomycosis (onychomycosis) is also referred to as onychomycosis, onychomycosis, refers to by dermatophyte, saccharomycete and non-skin
Disease caused by under mould (abbreviation mould) the infection deck of tinea bacterium or first.The incidence of disease of onychomycosis accounts for the 2% of general population
~18%, the global incidence of disease has bigger difference, and China north and south span is larger, and there is also regional difference for the incidence of disease.It is domestic current
General population morbidity data is deficient, only the survey data of the population of Shanghai the 1980s 110000, as a result prompts onychomycosis
Illness rate is 5.69%.The ratio of onychomycosis patient in the medical pedopathy patient of national multicenter epidemiology survey Dermatology Outpatient Department
Example is 15.7% (n=41329).But still lack the accurate morbidity data of large sample at present.
1. the cause of disease
Many fungies can cause a disease, and account for first place is dermatophyte, followed by saccharomycete and mould.The cause of disease of onychomycosis
Bacterium bag includes dermatophyte, saccharomycete and other moulds.Dermatophyte is that a group is close in form, physiology, antigenic characteristic co-relation
Fungi, the characteristics of its is common is close keratin, can invade the skin, hair and deck of human or animal.It is red in dermatophyte
Trichophyta is the most important pathogen for causing onychomycosis, is secondly alpha fungus；With the development of molecular biology, mesh
It is preceding that alpha fungus is reclassified, newly it is named as trichophyta (Trichophyton between toe (finger)
interdigitale).So far the dermatophyte for causing onychomycosis of document report shares 18 kinds, wherein 11 kinds of trichophyton,
6 kinds of Microsporon, a kind of Epidermophyton.Trichophyta, acrothesium floccosum are still domestic and international between Trichophyton rubrum, toe (finger)
The most common three kinds of dermatophytes for causing onychomycosis of most area.Trichophyta virulence is most strong between its middle toe (finger), its machine
Tool destructive power and proteolytic activity are all better than Trichophyton rubrum and acrothesium floccosum.
2. pathogenesis
Dermatophyte is keratinization with parent, into deck, the various enzymes of release, including proteolytic enzyme and esterase, decomposes angle
Albumen.First has certain defence capability, and in structure, first is protected by near-end nail fold and distal end deck closely connects with nail matrix
Take over control only microorganism invasion.First is also equipped with certain innate immune function, by produce antibacterial peptide (IL-37,
Cathelicidin) invading micro-organism is killed.But generally speaking, onychomadesis cellular immune function, first susceptible to fungi
The suitable fungi long term survival of plate.Chronic process is presented in onychomycosis morbidity, without inflammatory reaction.
Onychomycosis caused by candida albicans is more clear and definite in chronic mucous membrane cutaneous candidiasis and AIDS patient.Due to first
Lower candida albicans field planting is commonplace, so turning out candida albicans in first merely is difficult to prompting infection.Other moulds are in onychomycosis
In mechanism of causing a disease needs further investigation.
3. clinical characters
The deck of onychomycosis patient can show as it is muddy, thicken, separate, changing colour, atrophy, come off, tilt, surface it is recessed
Convex uneven, hook first and paronychia etc..
4. treatment
(1) Systemic administration：Itraconazole, Terbinafine, Fluconazole.(2) local application has：Amorolfine (5% A Moluo
Fragrant medicine A), 8% Ciclopirox Olamine medicine A etc..(3) non-drug therapy:(a) first is pulled out in operation；(b) chemistry removes first, and (c) other are non-
Drug therapy, there are laser therapy, optical dynamic therapy etc..(4) therapeutic alliance therapeutic alliance includes oral drugs and local externally applied drug
The joint of thing, oral drugs and (or) external used medicine are combined with non-drug therapy.
5. local topical medicine therapeutic profile
The local treatment of onychomycosis is with a long history, including chemically and physically two methods.Chemical method is conventional to be had
10%~30% glacial acetic acid, 10% tincture of iodine, 40% carbamide ointment, Salicylic Acid Formulations etc., or even somebody is using white balsamine, sheep
Onychomycosis is treated in hoof radical cure.Physical method includes pulling out first, file or electric grinder grinding deck etc..Relative to nail arrachement, use
Electric drill burrow above deck damage it is less, can equally solve the problem of Medicated Permeation.There is author to coordinate 2 weeks using clotrimazole external application
The drilling treatment onychomycosis of 1 time, more than the 80% of 96.2% patient sick first is cured in 92 patients after 12 weeks.Surgery pulls out first damage
Wound is big, uses less at present, and conventional cutin strips off medicine progress chemistry and pulls out first.
The content of the invention
It is an object of the invention to provide a kind of topical agent for treating onychomycosis, the present invention has softening keratin, quickly
Painless first of preventing or cure a disease, bactericidal antiphlogistic, improve local microcirculation and nutrition, promote the effect of first growth, medicament of the present invention be different from
The therapeutic scheme of onychomycosis is controlled outward, first with the quick painless first of preventing or cure a disease of A emulsifiable pastes, is dispelled the deck barrier of nail matrix dispenser, is made medicine
Agent is gone directly focus, is revolutionized and is generally gone through the drawbacks of deck dispenser of disease first can not arrive at focus.Eliminating nail matrix administration
B gels are used on the premise of barrier, it is rapid thoroughly to remove the pathogenic bacteria for killing lesions position, kill the pathogenic bacteria of onychomycosis, C
Liniment strong disinfecting, nail matrix and perionychium skin cleaning ambient are kept, reaches the effect not recurred.
The technical scheme is that a kind of topical agent for treating onychomycosis, by A emulsifiable pastes, B gels, C liniment three parts
Composition, wherein
A emulsifiable pastes are made up by weight of following bulk drugs：
Extracts from Flowers of Impatiens balsamina L 6-15 parts, basil oil 10-30 parts, calcium mercaptoacetate 40-65 parts, phosphoamide 35-65 parts,
Glycerine 25-40 parts, vaseline 30-55 parts, white oil 30-50 parts, octadecyl alcolol 35-50 parts, stearic acid 20-35 parts, monostearate are sweet
Grease 20-30 parts, peregal 30-60 parts, triclocarban 2-11 parts, polyethylene glycol (400) 45-70 parts, purified water add to 1000
Part.
B gels are made up by weight of following raw materials according：Basil oil 5-14 parts, cinnamon oil 6-15 parts, eucalyptus oil 5-17
Part, peppermint oil 5-16 parts, Berberine hydrochloride 0.5-2 parts, glycerine 40-70 parts, carbomer (940) 7-22 parts, Laurocapram 15-
25 parts, appropriate triethanolamine, polysorbate (80) 5-16 parts, natrium adetate 0.5-2 parts, purified water adds to 1000 parts.
C liniments are made up by weight of following raw materials according：Chlorhexidine acetate iodine 6-19 parts, basil oil 10-35 parts, lactic acid
15-24 parts, natrium adetate 0.5-2 parts, 65% ethanol add to 1000 parts.
The preparation technology of A emulsifiable pastes is：
Stearic acid, monoglyceride, white oil, octadecyl alcolol, vaseline, peregal are mixed into oil phase and heat and be warming up to 80 DEG C；Fourth
Fragrant basil rapidly joins, and stirs, and glycerine, phosphoamide, Extracts from Flowers of Impatiens balsamina L add aqueous phase, stir, and heating is simultaneously
It is warming up to 90 DEG C；Stirring is cooled to 80 DEG C.Oil phase is added aqueous phase, stirring and emulsifying；Triclocarban, polyethylene glycol (400) mix,
It is standby；Treat that lotion is cooled to 45 DEG C~55 DEG C, sequentially add triclocarban, polyethylene glycol (400) mixed liquor, calcium mercaptoacetate,
Stir and evenly mix.Discharging, stand, produce.
The preparation technology of B gels is：Berberine hydrochloride adds qs glycerin dispersing and dissolving, forms dispersion liquid, standby；Cloves sieve
Oil, cinnamon oil, peppermint oil, eucalyptus oil, Laurocapram mixing are strangled, polysorbate (80) is added and stirs and evenly mixs, form mixing
Liquid, it is standby；Carbomer, natrium adetate are spread in appropriate water, fully swelling, glycerine stirring are added, into gel-type vehicle；Will
Above-mentioned dispersion liquid and mixed liquor are added in matrix, are slowly added to quickly stir, and after uniform, added water to ormal weight, are continued to stir
Uniformly, add triethanolamine to adjust pH8~9, produce B gels.
The preparation technology of C liniments is：Chlorhexidine acetate iodine adds 65% ethanol to dissolve；Stirring adds basil oil, stirring
Uniformly；Sequentially add lactic acid, natrium adetate stirs；65% ethanol is added to ormal weight, is produced.
The features of the present invention
First, the breakthrough in the technology of the present invention, (1) employs the biochemical softening formula of disease first and removal technology, quick painless, keeps away
First excitant of having exempted to prevent or cure a disease before this is big and the drawbacks of softening efficiency is low (make prevent or cure a disease first shorten to 2~3 days by 10~15 days), section
Human-saving material resources, enhance the compliance of patient.(2) sick first removes, and enables medicament through focus rapidly, kills pathomycete,
Effectively improve pharmacy effect effect (concentration, time).(3) active components of plants not only there is stronger sterilization to make with cell repair
With, and improve the microcirculation of lesions position, the nutrition supply of nail matrix is enhanced, promotes new first to grow.(4) C liniments strength is killed
Bacterium, nail matrix and perionychium skin cleaning ambient are kept, reaches the effect not recurred.Ensure the therapeutic effect of onychomycosis.(5) this hair
Bright multi-level, the multi-faceted killing pathomycete using uniqueness, the various Propagation Methods and mode of pathomycete are blocked, are solved
Conventional medicine is difficult to eradicate the problem of onychomycosis rapidly through epidermal keratinocytes tissue,
2nd, its main component of the medicament of the present invention is made up of plants essential oil, alkaloid and chemical drug, avoids antibiotic
Using the generation side effect with antifungal drug drug resistance, reparation of the plant component to cell, maintenance function, a variety of medium-height grass are utilized
Medicine active component, molecule granularity is minimum, and plants essential oil penetrating power, which has by force, promotees Transdermal absorption effect, and medicament can quickly penetrate into skin
Under, it is without any side effects to human body.
3rd, medicament of the invention directly imposes on affected part, and Transdermal absorption, medicine component concentration is high, and medicine directly penetrates into focus
Deep skin tissue.Avoid the loss of medication amount and the poisoning to human viscera organ.
4th, the present invention passes through pharmacological evaluation and clinical verification, shows that this product has stronger antibacterial action；Clinical test,
This product has the effect of preferable to onychomycosis；It is to epiderm skin tissue, hypodermis not damaged, nonirritant, nontoxic pair
Effect.Laboratory research, clinical experience and the gains in depth of comprehension summarized in recent years create out simple and direct practical and effective " quick painless removal disease
First (focus)+medicament focus of going directly kills deep seated infections fungi+while creates rehabilitation control environment and prevent recurrent infection " three one
Autogenic therapy, solve the problem for how eliminating the cause of disease, the problem for solving deep medicament infiltration, solve the difficulty recurred more afterwards
Topic.
The correlative study profile test of medicament of the present invention
First, laboratory antibacterial tests research report (the commission Xi'an microorganism teaching and research room of Jiao great medical colleges of medicament of the present invention
Experiment)
Experimental result
1. sample to ETEC, staphylococcus aureus, candida albicans bacterium and chaff shape chlosma MIC,
MBC measurement results are shown in Table 1.
The experiment sample of table 1. is to ETEC, staphylococcus aureus, candida albicans bacterium, chaff shape fish-scale tinea bacterium
MIC and MBC measurement results (mg/ml)
* is noted in maximum experimental concentration 0.1g/ml without antibacterial/bactericidal action.
No. 2 samples are A cream, and No. 4 samples are positive control：1% terbinafine emulsifiable paste agent, No. 9 samples are B gels, No. 10
Sample is C liniments, and following table is same.
2. sample determines knot to MIC, MBC of Trichophyton rubrum, alpha fungus, microsporum canis and acrothesium floccosum
Fruit is shown in Table 2.
The experiment sample of table 2. is surveyed to Trichophyton rubrum, alpha fungus, microsporum canis, acrothesium floccosum MIC and MBC
Determine result (mg/ml)
Conclusion：Determined through experiment, A emulsifiable pastes, B gels, C liniments are respectively provided with stronger antibacterial, antifungic action.
2nd, clinical research test overview of the present invention
Onychomycosis (onychomycosis) is common clinical, frequently-occurring disease, belongs to the multiple difficult disease of clinic skin section.We grind
The external therapy of the Trinity pharmaceutical treatment onychomycosis of hair, safe, the liver renal toxicity of no medicinal preparation for oral administration.Constituent without
Antibiotic, it is the green remedy advocated at present.Further to control the effect of onychomycosis outside the checking present invention, to onychomycosis 48
Example samples above-mentioned therapy and treated, and treatment results are summarized as follows：
(1) general information
(1) inclusion criteria：Sex, age are unlimited, and may not influenceing the disease of Growth rate of fingernail, (such as hyperthyroidism, first subtracts
Deng)；It is previously normal without onychomycosis medical history and other onychonosus medical histories, deck appearance luster form；Nearly 3 months nails are without traumatosis
History；Hand skin intact unbroken person.
(2) exclusion standard：Pregnant woman, nursing period, the person that takes contraceptive；3 months inscribed to have received systemic antifungal drug and has controlled
Treatment person；Take the medicine that may influence first growth metabolism simultaneously；With liver, kidney, the heart, nervus pulmonalis systemic disease and psoriasis, wet
Exanthema patient.Therapeutic process interrupts the exclusion for the treatment of.
All object of observation clinical symptoms typical cases, and the direct microscopy of fungi is positive, non-system is using antimycotic in nearly 3 months
Drug therapy, be not in the mood for, liver, kidney, nervus pulmonalis systemic disease.Do not complete the regulation course for the treatment of and do not continue to complete follow-up examination person to reject
Case, it is not counted in the object of observation.Meet above-mentioned standard amounts to 48 selected, men 20, female 28；At 18~62 years old age, put down
Equal 39.5 years old；The course of disease 6 months~23 years, it is average 8.4 years.Nail onychomycosis 25, toenail nosomycosis 15, nail merge toe
Onychomycosis 8, involvement first number 196.
(2) treatment method
First the beautiful net A cream of first is externally applied at onychomycosis disease deck, about l~2mm is thick, changes within 1 day 1, C is used after removing disease first
Liquid deep layer is sterilized, and is haveed the function that outside antibacterial using B cream simultaneously and promoted new first fast-growth.Treated simultaneously during treatment
Tinea of feet and hands, it is ensured that tinea of feet and hands is cured simultaneously, and medication 28 days is 1 course for the treatment of, and 2 courses for the treatment of judge curative effect.
Curative effect determinate standard：Recovery from illness：Sick first is wholly absent, newborn deck smooth, bright color as disease-free deck, disease
First is cured completely, and newborn healthy first tissue substitute pathological tissues, nothing is repeatedly healing in 12 months.It is effective：Sick first regression >=
80%；Take a turn for the better：Sick first regression 50~79%；It is invalid：Sick first regression ＜ 50%.Fully recover, be effective total effective with total calculating that takes a turn for the better
Rate.Fungi evaluation of efficacy criteria is eliminated and not eliminated.
(3) result
Clinical recovery (sick first removes, and grows new first person) 43, cure rate 89.6%.Effective 2, take a turn for the better 1, it is total effective
Rate 95.8%, invalid (the non-improver of onychomycosis) 2.First of preventing or cure a disease therapeutic process few patients have mild pain sense, after drug withdrawal
Voluntarily fading, have no other adverse reactions.Wherein allergy sufferers 1.
(4) discuss
Onychomycosis (onychomycosis) is a kind of common disease and frequently-occurring disease of dept. of dermatology, there is certain infectiousness, is to cure at present
Learn treatment difficult point.The Basic disease cause of onychomycosis is that fungi invades deck surrounding skin or first undertissue, then secretes cutin egg
White enzyme decomposes cutin, destroys first tissue and causes infection.Primary treatments clinically are Oral antifungal agents and hand at present
Art is pulled out based on first, and because oral medicine side effect is larger, so not acceptable to all, operation pulls out first wound greatly and easily recurrence, therefore
Seeking effective local penetration sterilization therapy has important clinical meaning.The principle of this therapy is：The painless removal of fast softening
Sick first, so that reaching the optimal infiltration of medicine, so as to play bactericidal action.Three doses combination, the Trinity, have softening illness first,
Deep layer is sterilized and quickly grows first-class effect, and for controlling onychomycosis, curative effect is preferable.
It is used for sick first outside this therapy, it is easy to use, without any discomfort, and also administration time is not grown, uneasy to recur, Huan Zheyi
It is fine from property, safely and effectively.Compound or folk prescription external preparation the treatment onychomycosis of more simple first of preventing or cure a disease, therapy treatment first
Nosomycosis has focused on therapy rehabilitation overall process and prevention and control key point, and its advantage is curative effect height, short treating period, few side effects, operation letter
Just, recurrence rate is low, be current onychomycosis treatment in a kind of comparatively ideal therapy.
Brief description of the drawings
Fig. 1 is the production technological process of A emulsifiable pastes.
Fig. 2 is the production technological process of B gels.
Fig. 3 is the production technological process of C liniments.
Embodiment
First, A emulsifiable pastes are prepared
Bulk drug (unit is weighed by following weight：g)
Extracts from Flowers of Impatiens balsamina L 10g, basil oil 20g, calcium mercaptoacetate 50g, phosphoamide 50g, glycerine 30g, vaseline
40g, white oil 40g, octadecyl alcolol 40g, stearic acid 25g, glycerin monostearate 25g, peregal 40g, triclocarban 5g, poly- second two
Alcohol (400) 60g, purified water 565g (it is 1000g to add up)
Stearic acid, monoglyceride, white oil, octadecyl alcolol, vaseline, peregal are mixed into oil phase and heat and be warming up to 80 DEG C；Fourth
Fragrant basil rapidly joins, and stirs.Glycerine, phosphoamide, Extracts from Flowers of Impatiens balsamina L add aqueous phase, stir, and heating is simultaneously
It is warming up to 90 DEG C；Stirring is cooled to 80 DEG C.Oil phase is added aqueous phase, stirring and emulsifying；Triclocarban, polyethylene glycol (400) mix,
It is standby；Treat that lotion is cooled to 45 DEG C~55 DEG C, sequentially add triclocarban, polyethylene glycol (400) mixed liquor, calcium mercaptoacetate,
Stir and evenly mix.Discharging, stand, produce.
2nd, B gels are prepared
Bulk drug (unit is weighed by following weight：g)
Basil oil 10g, cinnamon oil 10g, eucalyptus oil 10g, peppermint oil 10g, Berberine hydrochloride 1g, glycerine 60g, card ripple
Nurse (940) 12g, Laurocapram 20g, appropriate triethanolamine, polysorbate (80) 10g, natrium adetate 1g, purified water add
To 1000 parts.
Berberine hydrochloride adds qs glycerin dispersing and dissolving, forms dispersion liquid, standby；Basil oil, cinnamon oil, peppermint
Oil, eucalyptus oil, Laurocapram mixing, add polysorbate (80) and stir and evenly mix, and form mixed liquor, standby；By carbomer,
Natrium adetate is spread in appropriate water, fully swelling, glycerine stirring is added, into gel-type vehicle；By above-mentioned dispersion liquid and mixing
Liquid is added in matrix, is slowly added to quickly stir, and after uniform, added water to ormal weight, is continued to stir, add triethanolamine to adjust
PH8~9, produce B gels.
3rd, C liniments are prepared
Bulk drug (unit is weighed by following weight：g,ml)
Chlorhexidine acetate iodine 10g, basil oil 20g, lactic acid 20g, natrium adetate 1g, 65% ethanol add to 1000
Part.
Chlorhexidine acetate iodine adds 65% ethanol to dissolve；Stirring adds basil oil, stirs；Sequentially add lactic acid,
Natrium adetate stirs；65% ethanol is added to ormal weight, is produced.4th, application method
1. first use A emulsifiable pastes
First A cream is externally applied at onychomycosis disease deck, about l~2mm is thick, changes within 1 day 1.The sick first of removal softening, 1~2 time
It can remove sick first.
2. time with B gels
B gels are applied to the onychomycosis affected part for removing disease first, daily 2~3 times, until growing new first.
3. C liniments are used again
By C liniments coating in onychomycosis affected part, daily 2~3 times, until growing new first.
Claims (2)
1. a kind of topical agent for treating onychomycosis, it is characterized in that be made up of A emulsifiable pastes, B gels, C liniment three parts,
Wherein A emulsifiable pastes are made up by weight of following bulk drugs：
Extracts from Flowers of Impatiens balsamina L 6-15 parts, basil oil 10-30 parts, calcium mercaptoacetate 40-65 parts, phosphoamide 35-65 parts, glycerine
25-40 parts, vaseline 30-55 parts, white oil 30-50 parts, octadecyl alcolol 35-50 parts, stearic acid 20-35 parts, glycerin monostearate
20-30 parts, peregal 30-60 parts, triclocarban 2-11 parts, polyethylene glycol (400) 45-70 parts, purified water add to 1000 parts；
B gels are made up by weight of following bulk drugs：
Basil oil 5-14 parts, cinnamon oil 6-15 parts, eucalyptus oil 5-17 parts, peppermint oil 5-16 parts, Berberine hydrochloride 0.5-2
Part, glycerine 40-70 parts, carbomer (940) 7-22 parts, Laurocapram 15-25 parts, appropriate triethanolamine, polysorbate
(80) 5-16 parts, natrium adetate 0.5-2 parts, purified water add to 1000 parts；
C liniments are made up by weight of following bulk drugs：
Chlorhexidine acetate iodine 6-19 parts, basil oil 10-35 parts, lactic acid 15-24 parts, natrium adetate 0.5-2 parts, 65% second
Alcohol adds to 1000 parts.
2. the topical agent for the treatment of onychomycosis as claimed in claim 1, it is characterized in that the preparation method of A emulsifiable pastes is：Stearic acid,
Glycerin monostearate, white oil, octadecyl alcolol, vaseline, peregal are mixed into oil phase and heat and be warming up to 80 DEG C；Basil oil
Rapidly join, and stir；Glycerine, phosphoamide, Extracts from Flowers of Impatiens balsamina L add aqueous phase, stir, and heat and are warming up to 90
℃；Stirring is cooled to 80 DEG C；Oil phase is added aqueous phase, stirring and emulsifying, forms lotion；Triclocarban, polyethylene glycol (400) are mixed
It is even, it is standby；Treat that lotion is cooled to 45 DEG C~55 DEG C, sequentially add triclocarban, polyethylene glycol (400) mixed liquor, TGA
Calcium, stir and evenly mix, discharge, stand, produce A emulsifiable pastes；
The preparation method of B gels is：Berberine hydrochloride adds qs glycerin dispersing and dissolving, forms dispersion liquid, standby；Clore basil
Oil, cinnamon oil, peppermint oil, eucalyptus oil, Laurocapram mixing, add polysorbate (80) and stir and evenly mix, form mixed liquor,
It is standby；Carbomer, natrium adetate are spread in appropriate water, fully swelling, glycerine stirring are added, into gel-type vehicle；Will be upper
State dispersion liquid and mixed liquor is added in matrix, be slowly added to quickly stir, after uniform, add water to ormal weight, it is equal to continue stirring
It is even, add triethanolamine to adjust pH8~9, produce B gels；
The preparation method of C liniments is：Chlorhexidine acetate iodine adds 65% ethanol to dissolve；Stirring adds basil oil, stirs；
Sequentially add lactic acid, natrium adetate stirs；65% ethanol is added to ormal weight, produces C liniments.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710817905.1A CN107519236A (en) | 2017-09-12 | 2017-09-12 | A kind of topical agent for treating onychomycosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710817905.1A CN107519236A (en) | 2017-09-12 | 2017-09-12 | A kind of topical agent for treating onychomycosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107519236A true CN107519236A (en) | 2017-12-29 |
Family
ID=60736556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710817905.1A Withdrawn CN107519236A (en) | 2017-09-12 | 2017-09-12 | A kind of topical agent for treating onychomycosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107519236A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107854515A (en) * | 2017-11-23 | 2018-03-30 | 铜陵市东方矿冶机械有限责任公司 | Compound carron oil and preparation method thereof |
| CN110227100A (en) * | 2019-07-31 | 2019-09-13 | 河南国匠足病医学研究院 | A kind of topical agent for treating onychomycosis |
| CN110833574A (en) * | 2018-08-16 | 2020-02-25 | 安徽世龙生物医药科技有限公司 | External preparation and preparation method thereof |
| CN110833573A (en) * | 2018-08-16 | 2020-02-25 | 安徽世龙生物医药科技有限公司 | External medicament for treating onychomycosis and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1236641A (en) * | 1999-05-19 | 1999-12-01 | 成都新蓉灰指甲研究所 | Process for preparing onychomycosis ointment |
-
2017
- 2017-09-12 CN CN201710817905.1A patent/CN107519236A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1236641A (en) * | 1999-05-19 | 1999-12-01 | 成都新蓉灰指甲研究所 | Process for preparing onychomycosis ointment |
Non-Patent Citations (5)
| Title |
|---|
| 傅超美: "《中药药剂学》", 31 August 2014, 中国医药科技出版社 * |
| 张媛: "《中药制剂技术》", 31 August 2012, 河南科学技术出版社 * |
| 戴玉: "《中医美容大全》", 31 December 1997, 中国中医药出版社 * |
| 林产化工与产品: "《林产化工与产品》", 30 June 1993, 化学工业出版社 * |
| 汪世龙: "甲丽净三位一体疗法治疗甲真菌病151例", 《现代中医药》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107854515A (en) * | 2017-11-23 | 2018-03-30 | 铜陵市东方矿冶机械有限责任公司 | Compound carron oil and preparation method thereof |
| CN110833574A (en) * | 2018-08-16 | 2020-02-25 | 安徽世龙生物医药科技有限公司 | External preparation and preparation method thereof |
| CN110833573A (en) * | 2018-08-16 | 2020-02-25 | 安徽世龙生物医药科技有限公司 | External medicament for treating onychomycosis and preparation method thereof |
| CN110227100A (en) * | 2019-07-31 | 2019-09-13 | 河南国匠足病医学研究院 | A kind of topical agent for treating onychomycosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105142728B (en) | Compositions and methods for treating surface wounds | |
| CN110585114B (en) | Bactericidal composition for regulating skin microbial flora and application thereof | |
| WO2008140200A1 (en) | External compositions for the skin | |
| CN107519236A (en) | A kind of topical agent for treating onychomycosis | |
| CN104922130B (en) | It is a kind of to be used to treat gelling agent of herpes zoster and preparation method thereof | |
| CN108135972B (en) | Application of mussel mucin product in treating and preventing melanin-related diseases | |
| CN107970275A (en) | A kind of topical agent for treating tinea of feet and hands | |
| EP2931324A1 (en) | Compositions and methods for tissue regeneration | |
| CN104688786A (en) | Externally used pharmaceutical composition, preparation method and application thereof | |
| CN106726896A (en) | A kind of beautifying health composition with anti-inflammatory bacteriostasis efficacy and preparation method thereof | |
| US11045503B2 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis | |
| CN105963243B (en) | A kind of borneol cinnamomum camphora essential oil sustained release emulsifiable paste and preparation method thereof for treating acne vulgaris | |
| CN110974861B (en) | Blumea balsamifera oil liposome | |
| CN102018780B (en) | Skin bacteriostatic agent and preparation method thereof | |
| CN103432049B (en) | Composition with deodorization function | |
| CN107174535A (en) | A kind of hyaluronic acid compositions and application with the transdermal reparation effect of anti-inflammatory | |
| RU2782695C1 (en) | Composition for external use "septisol" | |
| RU2407483C1 (en) | Method of prevention and treatment of dermatological diseases of animals and medication for its realisation | |
| CN103893553B (en) | A kind of surface of a wound Chinese medicine compound prescription film and preparation method thereof | |
| CN108066518A (en) | A kind of dog Chinese medicine bath lotion composition and preparation method thereof | |
| CN100387254C (en) | Suppository of Chinese traditional medicine and preparing method | |
| CN103623007B (en) | A kind of external-applied ointment and preparation and application thereof for the treatment of the ringworm of scalp | |
| JPH10120561A (en) | Skin preparation for improving sputum for external use | |
| CN101766731A (en) | Tea polyphenol acne resistant external preparation | |
| CN106074995A (en) | A kind of bactericidal composition for treating female sex organs inflammation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20171229 |
|
| WW01 | Invention patent application withdrawn after publication |